sensorion hearing loss

Sensorion Receives FDA Investigational New Drug Clearance for Arazasetron (SENS-401)

MONTPELLIER, FRANCE — French biotech firm Sensorion, which specializes in the development of novel therapies to restore, treat and prevent inner ear diseases such as hearing loss, tinnitus and vertigo, announced today that it has received the Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) to proceed with SENS-401, based on…

Read More
sensorion gene therapy hearing loss

Sensorion Announces Partnership Framework Agreement with Institut Pasteur on Gene Therapy Programs for Hearing Loss

MONTPELLIER, FRANCE — French biotech firm Sensorion has announced the signature of a research partnership framework agreement with Institut Pasteur (Paris) granting to Sensorion an option to obtain exclusive licenses to develop and market drug candidates in gene therapy coming from collaborative projects, for the restoration, treatment and prevention of hearing disorders. In accordance with…

Read More
sensorion gene therapy hearing loss

Sensorion Enters Exclusive Negotiations with Pasteur Institute for Hearing Loss Gene Therapy Programs

MONTPELLIER, FRANCE — Biotech firm Sensorion announced that it has entered into a letter of intent with the Paris, France-based Pasteur Institute to exclusively negotiate a framework agreement to obtain the exclusive licenses to develop and commercialize gene therapy product candidates for restoration, treatment and prevention of hearing loss disorders. The Pasteur Institute Unit of…

Read More
sensorion

Sensorion to Begin Patient Enrollment for Safety Study of Vertigo Drug, Seliforant

MONTPELLIER, FRANCE — Biotech firm Sensorion announced the initiation of patient enrollment in a Phase 2a study (SENS-111-202) to confirm the absence of certain side effects commonly experienced with meclizine (specifically, anticholinergic side effects like sedation and memory loss) during an evoked vestibular imbalance. SENS-111-202 is a randomized, double-blind, double-dummy, placebo-controlled, cross-over trial in patients designed…

Read More
cochlear sensorion hearing loss drug sens 401

Cochlear Ltd Announces Research Study Collaboration, and $1.9M Placement, with Sensorion

SYDNEY, AUSTRALIA — Hearing implant maker, Cochlear Ltd, announced a strategic collaboration with French biotech firm, Sensorion. The collaboration will examine therapeutic approaches using Sensorion’s investigative drug, SENS-401, in combination with cochlear implants. According to the press release, the preclinical studies will be initiated in 2018, with possible clinical trials beginining as early as 2019.…

Read More
hearing loss cisplatin drug sens-401

Study finds Sensorion’s Investigative Drug Prevented Cisplatin-Induced Hearing Loss By More Than 50 Percent

MONTPELLIER, FRANCE — French biotech firm, Sensorion, announced the upcoming publication this week in the Journal of Otology & Neurotology of a new study showing oral clinical-stage SENS-401 (the company’s investigative drug) significantly prevented cisplatin-induced hearing loss in preclinical models. Cisplatin, a commonly-used chemotherapy agent to treat various forms of cancer, causes significant levels of…

Read More